Optogenetic Neuromodulation Therapy
Severe Chronic Pain
Pre-clinicalActive
Key Facts
About Opsin Biotherapeutics
Opsin Biotherapeutics is pioneering a novel approach to chronic pain management using optogenetic gene therapy. The company's technology aims to deliver light-sensitive proteins to specific pain-blocking neurons in the spinal cord, enabling their activation with an external light source for precise, on-demand pain relief. Founded in 2020 and based in San Francisco, Opsin is in the preclinical development stage, targeting a massive market dominated by opioids and neuromodulation devices. Its success hinges on demonstrating safety and efficacy of its non-viral delivery and optogenetic platform in humans.
View full company profile